Treatment of Adolescent Suicide Attempters (TASA)

New York State Psychiatric Institute

Status and phase

Completed

Phase 3

Phase 2

Conditions

Suicide, Attempted

Depression

Treatments

Drug: citalopram

Behavioral: Cognitive Behavioral Therapy

Drug: bupropion

Drug: escitalopram

Drug: lithium

Drug: mirtazapine

Drug: venlafaxine

Drug: fluoxetine

Drug: sertraline

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00080158

DDTR B4-ARD

#4623

U10MH066750 (U.S. NIH Grant/Contract)

U10MH066775 (U.S. NIH Grant/Contract)

U10MH066769 (U.S. NIH Grant/Contract)

U10MH066762 (U.S. NIH Grant/Contract)

U10MH066778 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Full description

Suicide is the third leading cause of death in adolescents and is a major public health problem. Depression is the most common diagnosis for adolescent suicide attempts. Little is known about what treatment is best for these adolescents since they are usually excluded from participation in research studies.

Participants in this study will be randomly assigned to receive carefully monitored antidepressant medication with routine support and management, cognitive behavioral therapy (CBT), or a combination of antidepressant medication plus CBT.

Sex

All

Ages

12 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

At least one suicide attempt or interrupted attempt within the past 45 days
Continuously reside with a primary caretaker (parent, legal guardian, foster parent) for at least 6 months that can provide legal consent